ABSTRACT
There is growing recognition of the importance of nutritional factors in the maintenance of bone and joint health, and that nutritional imbalance combined with endocrine abnormalities may be involved in the pathogenesis of osteoarthritis (OA) and osteochondritis dissecans (OCD). Despite this, dietary programs have played a secondary role in the management of these connective tissue disorders. Articular cartilage is critically dependent upon the regular provision of nutrients (glucose and amino acids), vitamins (particularly vitamin C), and essential trace elements (zinc, magnesium, and copper). Therefore, dietary supplementation programs and nutraceuticals used in conjunction with non-steroidal, anti-inflammatory drugs (NSAIDs) may offer significant benefits to patients with joint disorders, such as OA and OCD. This article examines the available clinical evidence for the efficacy of nutraceuticals, antioxidant vitamin C, polyphenols, essential fatty acids, and mineral cofactors in the treatment of OA and related joint disorders in humans and veterinary species. This article also attempts to clarify the current state of knowledge. It also highlights the need for additional targeted research to elucidate the changes in nutritional status and potential alterations to the expression of plasma membrane transport systems in synovial structures in pathophysiological states, so that current therapy and future treatments may be better focused.
Subject(s)
Osteoarthritis/diet therapy , Osteoarthritis/drug therapy , Osteochondritis Dissecans/diet therapy , Osteochondritis Dissecans/drug therapy , Amino Acids/administration & dosage , Animals , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Bivalvia , Camellia sinensis/chemistry , Cartilage/chemistry , Cartilage/physiology , Chondroitin Sulfates/administration & dosage , Fatty Acids, Essential/administration & dosage , Flavonoids/administration & dosage , Glucosamine/administration & dosage , Glucose/administration & dosage , Humans , Nutritional Status , Obesity/complications , Osteoarthritis/etiology , Osteochondritis Dissecans/etiology , Phenols/administration & dosage , Polyphenols , Trace Elements/administration & dosage , Vitamins/administration & dosageABSTRACT
N(epsilon)-(carboxymethyl)lysine (CML) is an advanced glycation end product formed by non-enzymatic glycation and oxidation of proteins. The distribution pattern of CML-modified proteins in normal and osteoarthritic (OA) cartilage was investigated using specific antibodies. In healthy articular cartilage, immunoreactivity for CML was preferably found in the extracellular matrix (ECM) of the superficial layer. In OA samples, CML immunoreactivity was not restricted to the ECM of the superficial layer. Interestingly, OA chondrocytes showed a remarkable cytoplasmic immunoreactivity for CML. With the help of a western blot analysis CML-modified proteins between 68 and 39 kDa could be demonstrated in OA cartilage samples. These results suggest that the accumulation of CML adducts contributes to the matrix damage in osteoarthritis. Therefore, the inhibition of CML accumulation may represent an effective therapeutic strategy to prevent severe OA cartilage injury.
